The Times Highlights OriCol™ as a Breakthrough in Bowel Cancer Testing

Origin is proud to see The Times highlight the potential of OriCol™, our 90-second triomic test designed to transform bowel cancer assessment and reduce reliance on invasive colonoscopies. The article underscores OriCol™’s ability to spare more than 600,000 people each year from unnecessary procedures.

In an 800-patient clinical study, soon to be published in Nature Communications, OriCol™ accurately distinguished healthy patients from those likely to have bowel cancer or significant polyps—providing 80% of symptomatic patients with a rapid, safe all-clear.

Delivered in community settings by trained professionals, OriCol™ has already demonstrated the potential to reduce clinician waiting times from two weeks to just three days. Patients have described the procedure as “very quick, very easy and quite comfortable.”

More than a diagnostic test, OriCol™ represents the foundation of a faster, more accessible—and potentially preventive—bowel cancer pathway.

We would like to thank The Shrewsbury and Telford Hospital NHS Trust, Jo Williams, Jon Lacy-Colson, and Ben Spencer for their support of the TRIOMIC trial and for taking the time to engage with the Origin team.